MRSNEarnings•globenewswire•
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
Sentiment:Negative (5)
Summary
CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire